Samuel T. Workenhe

2.5k total citations
31 papers, 1.3k citations indexed

About

Samuel T. Workenhe is a scholar working on Immunology, Oncology and Genetics. According to data from OpenAlex, Samuel T. Workenhe has authored 31 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Immunology, 16 papers in Oncology and 14 papers in Genetics. Recurrent topics in Samuel T. Workenhe's work include Virus-based gene therapy research (14 papers), CAR-T cell therapy research (10 papers) and Immunotherapy and Immune Responses (10 papers). Samuel T. Workenhe is often cited by papers focused on Virus-based gene therapy research (14 papers), CAR-T cell therapy research (10 papers) and Immunotherapy and Immune Responses (10 papers). Samuel T. Workenhe collaborates with scholars based in Canada, United States and Sweden. Samuel T. Workenhe's co-authors include Karen Mossman, Frederick S.B. Kibenge, Molly Kibenge, Jonathan Pol, Matthew L. Rise, Brian D. Lichty, Guido Kroemer, Molly JT Kibenge, Marcos Godoy and Mark D. Fast and has published in prestigious journals such as The Journal of Immunology, Oncogene and Journal of Virology.

In The Last Decade

Samuel T. Workenhe

30 papers receiving 1.2k citations

Peers

Samuel T. Workenhe

IMMUN

GENET

ONCOL

Louisa S. Chard United Kingdom

Gail Henderson United States

Oliberto Sánchez Chile

Qi Qin China

Brian P. Dolan United States

Jayashree M. Paranjape United States

Patrick P. Ng United States

Carolina S. Ilkow Canada

Kangla Tsung United States

Laurent Poliquin Canada

Louisa S. Chard United Kingdom

Samuel T. Workenhe

258 ×0.4

IMMUN

532 ×1.1

GENET

508 ×1.0

ONCOL

714 ×2.0

239 ×1.3

Citations per year, relative to Samuel T. Workenhe Samuel T. Workenhe (= 1×) peers Louisa S. Chard

Countries citing papers authored by Samuel T. Workenhe

Since Specialization

Citations

This map shows the geographic impact of Samuel T. Workenhe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel T. Workenhe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel T. Workenhe more than expected).

Fields of papers citing papers by Samuel T. Workenhe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel T. Workenhe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel T. Workenhe. The network helps show where Samuel T. Workenhe may publish in the future.

Co-authorship network of co-authors of Samuel T. Workenhe

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel T. Workenhe. A scholar is included among the top collaborators of Samuel T. Workenhe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel T. Workenhe. Samuel T. Workenhe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Walsh, Scott R., Andrew Nguyen, Lan Chen, et al.. (2024). Level of Expression of MHCI-Presented Neoepitopes Influences Tumor Rejection by Neoantigen-Specific CD8+ T Cells. Cancer Immunology Research. 13(1). 84–97.

Workenhe, Samuel T., et al.. (2023). Determinants for Antitumor and Protumor Effects of Programmed Cell Death. Cancer Immunology Research. 12(1). 7–16. 3 indexed citations

Hoang, Huy‐Dung, Victoria H. Gilchrist, Xiao Xiang, et al.. (2023). Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1. Journal for ImmunoTherapy of Cancer. 11(3). e006408–e006408. 2 indexed citations

Sun, Yi, et al.. (2022). Viral-mediated activation and inhibition of programmed cell death. PLoS Pathogens. 18(8). e1010718–e1010718. 51 indexed citations

Vito, Alyssa, Omar Salem, Nader El-Sayes, et al.. (2021). Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells. Communications Biology. 4(1). 859–859. 16 indexed citations

Workenhe, Samuel T., Jonathan Pol, & Guido Kroemer. (2021). Tumor-intrinsic determinants of immunogenic cell death modalities. OncoImmunology. 10(1). 1893466–1893466. 30 indexed citations

Workenhe, Samuel T., Andrew Nguyen, David Bakhshinyan, et al.. (2020). De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors. Communications Biology. 3(1). 645–645. 41 indexed citations

Pol, Jonathan, Samuel T. Workenhe, Prathyusha Konda, Shashi Gujar, & Guido Kroemer. (2020). Cytokines in oncolytic virotherapy. Cytokine & Growth Factor Reviews. 56. 4–27. 48 indexed citations

Pol, Jonathan, Matthew J. Atherton, Kyle B. Stephenson, et al.. (2020). Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning. Journal for ImmunoTherapy of Cancer. 8(2). e000981–e000981. 19 indexed citations

10.

Martin, Nikolas T., Dominic G. Roy, Samuel T. Workenhe, et al.. (2019). Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer. Scientific Reports. 9(1). 1865–1865. 22 indexed citations

11.

Nguyen, Andrew, Louisa Ho, Samuel T. Workenhe, et al.. (2018). HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants. Cell Reports. 24(3). 642–654. 22 indexed citations

12.

Workenhe, Samuel T., et al.. (2015). Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells. Oncogene. 35(19). 2465–2474. 22 indexed citations

13.

Workenhe, Samuel T., Jonathan Pol, Brian D. Lichty, Derek T. Cummings, & Karen Mossman. (2013). Combining Oncolytic HSV-1 with Immunogenic Cell Death-Inducing Drug Mitoxantrone Breaks Cancer Immune Tolerance and Improves Therapeutic Efficacy. Cancer Immunology Research. 1(5). 309–319. 59 indexed citations

14.

Workenhe, Samuel T. & Karen Mossman. (2013). Rewiring cancer cell death to enhance oncolytic viro-immunotherapy. OncoImmunology. 2(12). e27138–e27138. 21 indexed citations

15.

Workenhe, Samuel T., et al.. (2013). Immunogenic HSV-mediated Oncolysis Shapes the Antitumor Immune Response and Contributes to Therapeutic Efficacy. Molecular Therapy. 22(1). 123–131. 95 indexed citations

16.

Kibenge, Frederick S.B., Marcos Godoy, Mark D. Fast, Samuel T. Workenhe, & Molly Kibenge. (2012). Countermeasures against viral diseases of farmed fish. Antiviral Research. 95(3). 257–281. 102 indexed citations

17.

Workenhe, Samuel T., Tiago S. Hori, Matthew L. Rise, Molly JT Kibenge, & Frederick S.B. Kibenge. (2009). Infectious salmon anaemia virus (ISAV) isolates induce distinct gene expression responses in the Atlantic salmon (Salmo salar) macrophage/dendritic-like cell line TO, assessed using genomic techniques. Molecular Immunology. 46(15). 2955–2974. 61 indexed citations

18.

Workenhe, Samuel T., et al.. (2008). Infectious salmon anaemia virus replication and induction of alpha interferon in Atlantic salmon erythrocytes. Virology Journal. 5(1). 36–36. 60 indexed citations

19.

Workenhe, Samuel T., Molly Kibenge, Tokinori Iwamoto, & Frederick S.B. Kibenge. (2008). Absolute quantitation of infectious salmon anaemia virus using different real-time reverse transcription PCR chemistries. Journal of Virological Methods. 154(1-2). 128–134. 19 indexed citations

20.

Workenhe, Samuel T., et al.. (2007). Demonstration of infectious salmon anaemia virus (ISAV) endocytosis in erythrocytes of Atlantic salmon. Virology Journal. 4(1). 13–13. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact